A61K 47/556
Enzyme catalyzed therapeutic agent [ecta]
Official title: {enzyme catalyzed therapeutic agent [ECTA]}
A61K47/556 (Enzyme catalyzed therapeutic agent [ecta]) appears on 58 US grants and 83 published applications in this corpus.
Search patents in A61K- Granted patents
- 58
- Published applications
- 83
- Assignees
- 51
- Inventors
- 153
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 4 |
| 2007 | 1 | 0 |
| 2008 | 2 | 4 |
| 2009 | 4 | 4 |
| 2010 | 0 | 7 |
| 2011 | 2 | 5 |
| 2012 | 2 | 5 |
| 2013 | 5 | 8 |
| 2014 | 6 | 2 |
| 2015 | 3 | 6 |
| 2016 | 1 | 3 |
| 2017 | 3 | 4 |
| 2018 | 6 | 6 |
| 2019 | 6 | 6 |
| 2020 | 4 | 3 |
| 2021 | 3 | 3 |
| 2022 | 2 | 3 |
| 2023 | 3 | 0 |
| 2024 | 1 | 2 |
| 2025 | 1 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- ASH1L inhibitors and methods of treatment therewith13 Jan 2026US 12,521,442 B2The Regents of the University of Michigan
- ASH1L degraders and methods of treatment therewith29 Apr 2025US 12,285,490 B2The Regents of the University of Michigan
- Compounds and methods for selective proteolysis of glucocorticoid receptors4 Jun 2024US 11,998,606 B2Board of Regents, The University of Texas System
- ASH1L inhibitors and methods of treatment therewith5 Dec 2023US 11,833,210 B2The Regents of the University of Michigan
- ASH1L degraders and methods of treatment therewith17 Oct 2023US 11,786,602 B2The Regents of the University of Michigan
- Ash1l degraders and methods of treatment therewith7 Nov 2024US 2024/0366774 A1The Regents of the University of Michigan
- Ash1l inhibitors and methods of treatment therewith22 Aug 2024US 2024/0277856 A1The Regents of the University of Mishigan
- Ash1l inhibitors and methods of treatment therewith15 Sep 2022US 2022/0288217 A1The Regents of the University of Michigan
- Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand14 Jul 2022US 2022/0218831 A1Nemucore Medical Innovations, Inc.
- Ash1l degraders and methods of treatment therewit10 Mar 2022US 2022/0072142 A1The Regents of the University of Michigan
Most cited
By later US patents
- Cytotoxic compounds and conjugates121US 7,517,903 B2Medarex, Inc. · 2009
- 1AP E3 ligase directed proteolysis targeting chimeric molecules52US 10,336,744 B2GlaxoSmithKline Intellectual Property Development Limited · 2019
- Controlled release of phenolic opioids31US 8,217,005 B2Signature Therapeutics, Inc. · 2012
- Enzyme catalyzed therapeutic agents29US 6,245,750 B1NewBiotics, Inc. · 2001
- Chemical linkers and cleavable substrates and conjugates thereof26US 8,461,117 B2Medarex, Inc. · 2013